Pre-existing diabetes mellitus in patients with multiple myeloma

European Journal of Haematology

Volumn 89, Issue 4, 2012, Pages 320-327

  Chou, Yi Sheng ^a,b   Yang, Ching Fen ^a,b   Chen, Harn Shen ^a,b   Yang, Sheng Hsiang ^a,b   Yu, Yuan Bin ^a,b   Hong, Ying Chung ^a,b   Liu, Chun Yu ^a,b   Gau, Jyh Pyng ^a,b   Liu, Jin Hwang ^a,b   Chen, Po Min ^a,b   Chiou, Tzeon Jye ^a,b   Tzeng, Cheng Hwai ^a,b   Hsiao, Liang Tsai ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

All cause mortality; Hyperglycaemia; Hypoglycaemia; Multiple myeloma; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84866433650     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01828.x     Document Type: Article

References (45)

1. Yancik R Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-83.
2. Turesson I, Velez R, Kristinsson SY, Landgren O Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010;85:225-30.
3. Jagannath S Treatment of patients with myeloma with comorbid conditions: considerations for the clinician. Clin Lymphoma Myeloma 2008;8(Suppl 4):S149-56.
4. Shaw JE, Sicree RA, Zimmet PZ Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
5. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
6. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-53.
7. Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R, Engelhardt M Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011;1:e35.
8. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042-9.
9. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31.
10. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011;154:76-103.
11. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
12. Mehta J, Cavo M, Singhal S How I treat elderly patients with myeloma. Blood 2010;116:2215-23.
13. Libourel EJ, Sonneveld P, van der HB, de Maat MP, Leebeek FW High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010;116:22-6.
14. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
15. Barlogie B, Smith L, Alexanian R Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
16. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7.
17. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
18. Lam EK, Batty GD, Huxley RR, et al. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol 2011;22:730-8.
19. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
20. Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348-54.
21. Yang SH, Teng HW, Hong YC, et al. International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. Ann Hematol 2012;91:93-102.
22. Hsiao LT, Yang CF, Yang SH, et al. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. Eur J Haematol 2012;88:159-66.
23. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
25. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
26. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
27. Durie BG, Salmon SE A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
29. Knudsen LM, Hjorth M, Hippe E Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65:175-81.
30. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007;92:546-9.
31. Li J, Zhou DB, Jiao L, Duan MH, Zhang W, Zhao YQ, Shen T Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma 2009;9:394-8.
32. Faiman B, Bilotti E, Mangan PA, Rogers K Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12:53-63.
33. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011;29:40-6.
34. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-64.
35. DeCensi A, Gennari A Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011;29:7-10.
36. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, Goldschmidt H, Klein B Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 2010;24:1940-50.
37. Hwang SJ, Tsai JC, Chen HC Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton) 2010;15(Suppl 2):3-9.
38. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
39. Boddana P, Caskey F, Casula A, Ansell D UK Renal Registry 11th Annual Report (December 2008): Chapter 14 UK Renal Registry and international comparisons. Nephron Clin Pract 2009;111(Suppl 1):c269-76.
40. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61.
41. Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003;42:87-95.
42. Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience. Crit Rev Oncol Hematol 2011;79:31-42.
43. Winearls CG Acute myeloma kidney. Kidney Int 1995;48:1347-61.
44. Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009;113:4614-26.
45. Peng LN, Lin MH, Lai HY, Hwang SJ, Chen LK, Chiou ST Risk factors of new onset diabetes mellitus among elderly Chinese in rural Taiwan. Age Ageing 2010;39:125-8.